PDLIM7 and nasopharyngeal carcinoma: Based on these studies, we believed that the sequence-specific RNAi targeting EBV oncogene such as LMP1 would enhance anti-tumor activity with less off-target effects, that the combination or targeted treatment could both suppress the cancer cell biological action and provoke the host immune system to promote anti-tumor immunity in NPC.